Blood test may guide chemo decisions for advanced breast cancer

NCT ID NCT01349842

Completed Knowledge-focused Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring circulating tumor cells (CTCs) in the blood can help doctors decide when to switch chemotherapy for women with metastatic breast cancer that has worsened after two prior treatments. The trial involved 265 women and compared standard care with CTC-guided treatment decisions. The goal was to see if this approach improves overall survival and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER DUCTAL INFILTRATING METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma invasive ductal breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DUCTAL INFILTRATING METASTATIC

Contacts and locations

Locations

Centre Georges Francois Leclerc

Dijon, 21079, France
Chu Limoges

Limoges, 87042, France
Clinique Victor Hugo

Le Mans, 72000, France
Hopital Saint Louis

Paris, 75475, France
Institut Curie

Paris, 75005, France
Institut Rene Huguenin Curie

Saint-Cloud, 92210, France
Institut de Canacerologie de L'Ouest

Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.